Screener
Amneal Pharmaceuticals, Inc. AMRX Injectable — Net revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Oral solid | $175,172 | $178,262 | $346,272 | $357,215 |
| Transdermal | 67,038 | 40,710 | 141,001 | 83,773 |
| Auto-Injector | 62,214 | 66,594 | 104,126 | 114,754 |
| Injectable | 56,783 | 34,646 | 106,721 | 69,434 |
| Biosimilar | 29,128 | 25,248 | 51,429 | 53,788 |
| Oral liquid | 10,371 | 17,879 | 22,463 | 41,427 |
| Other dosage forms (1) | 81,594 | 68,185 | 128,206 | 124,607 |
| Subtotal dosage forms | 482,300 | 431,524 | 900,218 | 844,998 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s injectable — net revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) reported injectable — net revenue of $56.78M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s injectable — net revenue changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s injectable — net revenue increased by 63.9% year-over-year, from $34.65M to $56.78M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s injectable — net revenue?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s injectable — net revenue has grown at a -5.1% compound annual growth rate (CAGR), from $188.94M to $161.24M.
- What does injectable — net revenue mean?
- This metric represents the total gross sales generated from the injectable pharmaceutical product line after accounting for returns, allowances, and rebates. It serves as a key indicator of the market demand and commercial performance for sterile, parenteral dosage forms within the company's portfolio. Monitoring this revenue stream helps investors assess the competitive positioning and growth trajectory of the company's specialized injectable manufacturing capabilities.
Ask your AI about Amneal Pharmaceuticals, Inc.'s injectable — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude